arrow
P

Paul R. Young

University of Queensland
H指数:67
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety and Immunogenicity of a Severe Acute Respiratory Syndrome Coronavirus 2 Spike Subunit Vaccine Stabilized in the Prefusion Conformation by a Second-Generation Molecular Clamp and Evaluated in Adults Aged 18-55 Years: A Randomized, Double-Blind, Active Comparator, Phase I Trial

一项利用第二代分子夹稳定前融合构象的严重急性呼吸综合征冠状病毒2刺突亚单位疫苗的安全性与免疫原性研究:一项在18-55岁成人中进行的随机、双盲、活性对照、I期临床试验

2025-12-010
PRE
Author Correction: A single residue in the yellow fever virus envelope protein modulates virion architecture and antigenicity

作者更正:黄热病毒包膜蛋白中的一个氨基酸残基调节病毒粒子的结构和抗原性

2025-11-050
OAAI
Nipah virus vaccines evaluated in pigs as a ‘One Health’ approach to protect public health

尼帕病毒疫苗在猪中的评估作为一种“一种健康”方法来保护公共卫生

2025-07-230
OAAI
A nanobody-based therapeutic targeting Nipah virus limits viral escape

靶向尼帕病毒的基于纳米抗体的治疗剂限制了病毒逃逸

2025-07-080
PRE
Dynamin independent endocytosis is an alternative cell entry mechanism for multiple animal viruses
2024-11-141
OAAI
Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial

使用高密度微阵列贴片递送的麻疹和风疹疫苗的安全性,耐受性和免疫原性: 一项随机,部分双盲,安慰剂对照的I期临床试验的结果

2023-11-176
OAAI
Long-term safety and immunogenicity of an MF59- adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or >56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial
2023-11-011
OAAI
Polygenic risk scores are associated with atrial electrophysiologic substrate abnormalities and outcomes after atrial fibrillation catheter ablation
2023-08-013
OAAI
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein
2022-11-0189
OAAI